Titan Pharma (TTNP)

Titan Pharmaceuticals Inc was incorporated in Delaware in February 1992. The Company is a specialty pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Its product development programs engaged mainly in important pharmaceutical markets with significant unmet medical needs and commercial potential. The Company is directly developing its product candidates and also utilizes corporate, academic and government partnerships as appropriate. Such collaborations have helped to fund product development and have enabled the Company to retain significant economic interest in its products. Its main asset is Probuphine, the first slow release implant formulation of buprenorphine in development for the long term maintenance treatment of opioid dependence. It is designed to maintain a stable, around the clock blood level of the medicine in patients for six months following a single treatment. Probuphine is the first product to utilize ProNeura, its novel, proprietary, continuous drug delivery technology. Its ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions. It is currently evaluating drugs and disease settings for opportunities to develop this drug delivery technology for other potential treatment applications in situations where conventional treatment is limited by variability in blood drug levels and poor patient compliance. Fanapt (iloperidone) is another product, which is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis in the U.S. The manufacturing of Probuphine has mainly been conducted at DPT Laboratories, Inc. The Company competes with other pharmaceutical companies and specialized biotechnology companies. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.